Armed with $137M fund, Signet launch­es hunt for a dozen new biotech plays

Signet Health­care Part­ners is get­ting the year start­ed by rolling out a new, $137 mil­lion biotech fund.

The New York-based group won’t win any awards for the biggest fund to hit the in­dus­try as VCs make off with a string of record sums. But it’s now lin­ing up about a dozen new port­fo­lio plays.

The 19-year-old fund has ac­cu­mu­lat­ed a large port­fo­lio over the years, in­vest­ing in firms like Pfenex, one of 45 up­starts they’ve backed with more than $400 mil­lion. And they’re look­ing to in­vest up to $15 mil­lion in each new com­pa­ny they back.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.